[go: up one dir, main page]

SMT202000023T1 - Coniugati di farmaco-anticorpo - Google Patents

Coniugati di farmaco-anticorpo

Info

Publication number
SMT202000023T1
SMT202000023T1 SM20200023T SMT202000023T SMT202000023T1 SM T202000023 T1 SMT202000023 T1 SM T202000023T1 SM 20200023 T SM20200023 T SM 20200023T SM T202000023 T SMT202000023 T SM T202000023T SM T202000023 T1 SMT202000023 T1 SM T202000023T1
Authority
SM
San Marino
Prior art keywords
drug conjugates
antibody drug
antibody
conjugates
drug
Prior art date
Application number
SM20200023T
Other languages
English (en)
Inventor
Solloso Andrés Francesch
Marchante Cármen Cuevas
Correa Juan Manuel Domínguez
García-Ibarrola María Garranzo
Alonso María José Munoz
Madrid Francisco Sánchez
Hernández Juan Manuel Zapata
Arroyo Alicia García
Pecharromán Maria Ángeles Ursa
Original Assignee
Pharma Mar Sa
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharma Mar Sa filed Critical Pharma Mar Sa
Publication of SMT202000023T1 publication Critical patent/SMT202000023T1/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6801—Drug-antibody or immunoglobulin conjugates defined by the pharmacologically or therapeutically active agent
    • A61K47/6803—Drugs conjugated to an antibody or immunoglobulin, e.g. cisplatin-antibody conjugates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6849—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a receptor, a cell surface antigen or a cell surface determinant
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/68—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment
    • A61K47/6835—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site
    • A61K47/6851—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell
    • A61K47/6855—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an antibody, an immunoglobulin or a fragment thereof, e.g. an Fc-fragment the modifying agent being an antibody or an immunoglobulin bearing at least one antigen-binding site the antibody targeting a determinant of a tumour cell the tumour determinant being from breast cancer cell
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/16—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member
    • C07D309/28—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having one double bond between ring members or between a ring member and a non-ring member with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D309/30—Oxygen atoms, e.g. delta-lactones
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D309/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings
    • C07D309/32—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only ring hetero atom, not condensed with other rings having two double bonds between ring members or between ring members and non-ring members
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/12—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a chain containing hetero atoms as chain links

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Cell Biology (AREA)
  • Oncology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Hematology (AREA)
  • Medicinal Preparation (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Peptides Or Proteins (AREA)
  • Pyrane Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
SM20200023T 2013-05-31 2014-06-02 Coniugati di farmaco-anticorpo SMT202000023T1 (it)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GBGB1309807.4A GB201309807D0 (en) 2013-05-31 2013-05-31 Antibody drug conjugates
EP14732514.6A EP3003386B1 (en) 2013-05-31 2014-06-02 Antibody drug conjugates
PCT/EP2014/061392 WO2014191578A1 (en) 2013-05-31 2014-06-02 Antibody drug conjugates

Publications (1)

Publication Number Publication Date
SMT202000023T1 true SMT202000023T1 (it) 2020-03-13

Family

ID=48805601

Family Applications (1)

Application Number Title Priority Date Filing Date
SM20200023T SMT202000023T1 (it) 2013-05-31 2014-06-02 Coniugati di farmaco-anticorpo

Country Status (30)

Country Link
US (2) US11224663B2 (it)
EP (1) EP3003386B1 (it)
JP (1) JP6412114B2 (it)
KR (2) KR102340681B1 (it)
CN (1) CN105451775B (it)
AR (2) AR096461A1 (it)
AU (1) AU2014273052B2 (it)
BR (1) BR112015029816B1 (it)
CA (1) CA2914041C (it)
CL (1) CL2015003481A1 (it)
CY (1) CY1122662T1 (it)
DK (1) DK3003386T3 (it)
ES (1) ES2778045T3 (it)
GB (1) GB201309807D0 (it)
HR (1) HRP20200032T1 (it)
IL (1) IL242571B (it)
LT (1) LT3003386T (it)
MX (1) MX356431B (it)
MY (1) MY176579A (it)
NZ (1) NZ715646A (it)
PL (1) PL3003386T3 (it)
PT (1) PT3003386T (it)
RS (1) RS59855B1 (it)
RU (1) RU2669812C2 (it)
SG (1) SG11201509563UA (it)
SI (1) SI3003386T1 (it)
SM (1) SMT202000023T1 (it)
UA (1) UA119327C2 (it)
WO (1) WO2014191578A1 (it)
ZA (1) ZA201508487B (it)

Families Citing this family (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20170058043A1 (en) * 2014-12-06 2017-03-02 H. Lee Moffitt Cancer Center And Research Institute, Inc. Bispecific antibody for cancer immunotherapy
CA2994544C (en) * 2015-08-03 2021-03-30 Enb Therapeutics, Llc Compositions and methods for treating cancers associated with etbr activation
KR102456433B1 (ko) 2016-03-02 2022-10-19 에자이 알앤드디 매니지먼트 가부시키가이샤 에리불린-기반 항체-약물 콘주게이트 및 사용 방법
AU2017346401B2 (en) * 2016-10-17 2021-05-20 Shenzhen Enduring Biotech, Ltd. Long acting multi-specific molecules and related methods
EP3381474A1 (en) * 2017-03-27 2018-10-03 Alfasigma S.p.A. Histone deacetylase inhibitors-based antibody drug conjugates (adcs) and use in therapy
JOP20190254A1 (ar) 2017-04-27 2019-10-27 Pharma Mar Sa مركبات مضادة للأورام
MX2020005565A (es) * 2017-11-30 2020-08-20 Seattle Genetics Inc Proceso para la preparacion de compuestos enlazantes de farmaco.
RU2020117156A (ru) * 2017-12-01 2022-01-04 Эббви Инк. Конъюгаты анти-cd40 антитела и лекарственного средства
EA202091672A1 (ru) 2018-01-08 2021-02-01 Регенерон Фармасьютикалз, Инк. Стероиды и их антитело-конъюгаты
CA3117145A1 (en) * 2018-10-21 2020-04-30 Slsg Limited Llc Combination immunotherapy for treatment of triple-negative breast cancer
TWI824043B (zh) * 2018-10-25 2023-12-01 西班牙商瑪製藥股份有限公司 藥物抗體共軛物
EP3898651A2 (en) 2018-12-21 2021-10-27 Regeneron Pharmaceuticals, Inc. Tubulysins and protein-tubulysin conjugates
CN113727734A (zh) * 2019-05-02 2021-11-30 乐高化学生物科学股份有限公司 包含具有tris结构的连接子的配体-药物偶联物
WO2020222573A1 (ko) * 2019-05-02 2020-11-05 주식회사 레고켐 바이오사이언스 트리스 구조를 가지는 링커를 포함하는 리간드-약물 접합체
IL287938B2 (en) * 2019-05-10 2025-07-01 Takeda Pharmaceuticals Co Antibody-drug conjugates
EP3760233B1 (en) * 2019-05-20 2023-07-12 MabPlex International Co., Ltd. One-pot preparation process for antibody drug conjugate intermediate
PT3833657T (pt) * 2019-07-31 2022-09-28 Advanced Biodesign Compostos de aminotiolester e seus usos
CA3175426A1 (en) * 2020-04-21 2021-10-28 Alfonso Latorre Lozano Drug antibody conjugates
CN114262377B (zh) * 2021-10-28 2024-03-22 新疆优迈生物技术有限公司 一种阻断cd70与其配体cd27结合的抗人cd70纳米抗体的制备方法及其编码序列
CN115873066A (zh) * 2022-07-27 2023-03-31 吉林省博大伟业制药有限公司 一种抗体偶联药物连接子的合成方法

Family Cites Families (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2802205C (en) 2002-07-31 2016-01-19 Seattle Genetics, Inc. Drug conjugates and their use for treating cancer, an autoimmune disease or an infectious disease
WO2004073656A2 (en) * 2003-02-20 2004-09-02 Seattle Genetics, Inc. Anti-cd70 antibody-drug conjugates and their use for the treatment of cancer and immune disorders
US8088387B2 (en) 2003-10-10 2012-01-03 Immunogen Inc. Method of targeting specific cell populations using cell-binding agent maytansinoid conjugates linked via a non-cleavable linker, said conjugates, and methods of making said conjugates
EP1817059A2 (en) 2004-12-01 2007-08-15 Genentech, Inc. Conjugates of 1,8-bis-naphthalimides with an antibody
EP1864682A1 (en) * 2006-06-09 2007-12-12 Sanofi-Aventis Leptomycin derivatives
EP2404912A3 (en) * 2006-06-16 2012-07-25 Pharma Mar S.A. Process and intermediates for the preparation of antitumoral dihydropyran-2-one compounds
CN101903367B (zh) * 2007-12-20 2015-08-05 法马马有限公司 抗肿瘤化合物
EP2300483A1 (en) 2008-05-23 2011-03-30 Wyeth LLC Triazine compounds as p13 kinase and mtor inhibitors
MX2011000509A (es) 2008-07-15 2011-04-05 Genentech Inc Conjugados derivados de antraciclina, proceso para su preparacion y su uso como compuestos antitumorales.
WO2010149688A2 (en) * 2009-06-24 2010-12-29 Pharma Mar, S.A. Antitumoral compounds

Also Published As

Publication number Publication date
GB201309807D0 (en) 2013-07-17
MX2015016417A (es) 2016-07-05
KR20160030132A (ko) 2016-03-16
US20220168436A1 (en) 2022-06-02
ZA201508487B (en) 2017-11-29
EP3003386B1 (en) 2019-10-16
LT3003386T (lt) 2020-01-27
BR112015029816A2 (pt) 2017-07-25
AR123672A2 (es) 2023-01-04
AR096461A1 (es) 2015-12-30
US11224663B2 (en) 2022-01-18
BR112015029816B1 (pt) 2022-10-04
KR20210156848A (ko) 2021-12-27
US12410148B2 (en) 2025-09-09
DK3003386T3 (da) 2020-01-27
WO2014191578A1 (en) 2014-12-04
CA2914041A1 (en) 2014-12-04
PL3003386T3 (pl) 2020-04-30
SI3003386T1 (sl) 2020-03-31
IL242571B (en) 2019-10-31
CL2015003481A1 (es) 2016-08-19
KR102340681B1 (ko) 2021-12-20
RU2015156499A3 (it) 2018-03-27
MX356431B (es) 2018-05-29
MY176579A (en) 2020-08-17
AU2014273052A1 (en) 2016-01-28
ES2778045T3 (es) 2020-08-07
NZ715646A (en) 2019-05-31
CY1122662T1 (el) 2021-03-12
JP2016526042A (ja) 2016-09-01
PT3003386T (pt) 2020-01-21
HRP20200032T1 (hr) 2020-03-20
CN105451775A (zh) 2016-03-30
JP6412114B2 (ja) 2018-10-24
RU2669812C2 (ru) 2018-10-16
CA2914041C (en) 2021-12-07
AU2014273052B2 (en) 2018-03-08
RU2015156499A (ru) 2017-06-30
UA119327C2 (uk) 2019-06-10
KR102448393B1 (ko) 2022-09-28
CN105451775B (zh) 2019-09-06
EP3003386A1 (en) 2016-04-13
US20160129128A1 (en) 2016-05-12
SG11201509563UA (en) 2015-12-30
RS59855B1 (sr) 2020-02-28

Similar Documents

Publication Publication Date Title
IL241277A0 (en) Antibody-drug conjugates
ZA201508487B (en) Antibody drug conjugates
IL244816A0 (en) Protein-polymer-drug conjugates
IL252015A0 (en) Antibody drug conjugates
IL245009A0 (en) Attach a drug from a protein and a polymer
IL240438A0 (en) New antibody conjugates and their uses
EP2968600A4 (en) Antibody drug conjugates
IL244712A0 (en) Anti-pdl1 antibody compositions
IL250189A0 (en) Anti–cdh6 antibody drug conjugates
ZA201502267B (en) Pyrrolobenzodiazepine-anti-her2 antibody conjugates
PL2906253T3 (pl) Koniugaty pirolobenzodiazepina-przeciwciało anty-psma
LT2906251T (lt) Pirolobenzodiazepino-anti-cd22 antikūno konjugatai
SG11201605260VA (en) Var2csa-drug conjugates
IL240886A0 (en) Antibody formulations
GB201300706D0 (en) Antibody
LU92659B1 (en) Glycooptimized antibody drug conjugates
SG11201604503XA (en) Cytotoxic antibody
GB201301845D0 (en) Antibody delivery